弥合差距:CKM综合征指南导向药物治疗的可及性与实施差异
Closing the gap: disparities in access to and implementation of guideline-directed medical therapy for CKM syndrome
Magdalena Madero在Nature Reviews Nephrology发表评论文章,指出CKM综合征指南导向药物治疗(GDMT)虽有充分循证支持但实际采用率偏低。文章认为结构性、经济性和公平性障碍需被克服,才能实现从高收入国家专科诊所到低资源地区基层医疗的GDMT有效实施。
- Comment
- Published: 16 October 2026
Nature Reviews Nephrology (2026) Cite this article
Despite robust evidence supporting guideline-directed medical therapy (GDMT) for cardiovascular–kidney–metabolic syndrome, uptake remains low. Structural, economic and equity-related barriers must be overcome to enable effective implementation of GDMT across settings from subspecialty clinics in high-income countries to primary care settings in low-resource regions.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
References
Rangaswami, J., Lo, K. B. & Ndumele, C. E. The therapeutic approach to cardiovascular–kidney–metabolic syndrome. Nat. Rev. Nephrol. https://doi.org/10.1038/s41581-026-01109-6 (2026).
Shin, J.-I. et al. Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems. J. Am. Coll. Cardiol. 84, 683–693 (2024).
Kovesdy, C. P. et al. Real-world SGLT2 inhibitor (SGLT2i) use in patients with CKD in the United States [abstract]. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.202592d27ygq (2025).
Jelwan, Y. et al. Finerenone prescriptions in the United States (2021–2024) by physician specialty: analysis of use and potential in the cardiovascular-kidney-metabolic space. J. Am. Heart Assoc. 15, e046837 (2026).
Khan, S. S. et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation 149, 430–449 (2024).
Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).
Pagidipati, N. J. et al. Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial. JAMA 329, 1261–1270 (2023).
Zheng, J., Mednick, T., Heidenreich, P. A. & Sandhu, A. T. Pharmacist- and nurse-led medical optimization in heart failure: a systematic review and meta-analysis. J. Card. Fail. 29, 1000–1013 (2023).
Eberly, L. A. et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum 2, e214182 (2021).
GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 2461–2482 (2025).
López, D. S., Hernández Vargas, J. A., Urina-Jassir, M., Urina-Triana, M. & Franco, O. H. Reducing the gap of chronic kidney disease in low- and middle-income countries: what is missing? Lancet Reg. Health Am. 28, 100625 (2023).
Bello, A. K. et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob. Health 12, e382–e395 (2024).
World Health Organization. The Selection and Use of Essential Medicines 2021: Report of the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines (WHO Technical Report Series No. 1035) (WHO, 2021).
Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC). Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Lancet Diabetes Endocrinol. 9, 825–836 (2021).
Author information
Authors and Affiliations
Department of Nephrology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
Magdalena Madero
Authors
- Magdalena Madero
Corresponding author
Correspondence to Magdalena Madero.
Ethics declarations
Competing interests
M.M. has consulted for AstraZeneca, Bayer, and Boehringer Ingelheim, provided expert testimonies for AstraZeneca, Bayer, and Boehringer Ingelheim and received grant funding or has pending grants from AstraZeneca, Bayer, Boehringer and the Renal Research Institute. She has also received travel support from AstraZeneca.
About this article
Cite this article
Madero, M. Closing the gap: disparities in access to and implementation of guideline-directed medical therapy for CKM syndrome. Nat Rev Nephrol (2026). https://doi.org/10.1038/s41581-026-01136-3
Published: 16 October 2026
Version of record: 16 October 2026
DOI: https://doi.org/10.1038/s41581-026-01136-3
来源:Nature 健康护理主题 · nature.com